Benzinga's Microcap Movers for Wednesday October 24, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Amryis (NASDAQ: AMRS), the Emeryville, CA integrated renewable products company, rose 16.39% Wednesday on almost twice average volume.
A report from Seeking Alpha published by Market Watch, shows Amryis the leader among biotech stocks in insider buys.
Amryis closed at $2.84 on Wednesday.
Cereplast (NASDAQ: CERP), the El Segundo, CA manufacturer of proprietary biobased, sustainable bioplastics, rose 12.90% Wednesday on twice average volume.
Cereplast announced Wednesday that Cereplast Hybrid 651D has won the MATERIALICA Design + Technology 2012 silver award for outstanding innovation in the "Material" category. The awards ceremony took place in Munich, Germany at the 15th annual trade fair, MATERIALICA--Lightweight Design for New Mobility, on the evening of October 23, 2012.
Cereplast closed at $0.21 on Wednesday.
Kips Bay Medical
Shares of Kips Bay Medical (NASDAQ: KIPS), the Minneapolis, MN medical device company, rose 26.27% Wednesday on 6 times average volume.
Dr. Enrico Ferrari of Lausanne will present on Kips Bay's eSVS Mesh on October 27th, 2012 at the 26th Annual Meeting of the European Association of Cardiothoracic Surgeons.
Kips Bay Medical closed at $1.49 on Wednesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.